SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for the second year in a row, it has been named a BioSpace 2024 Best Place to Work in the small employer category.
“This award acknowledges the commitment we’ve made to ensuring Anaptys provides our employees with an exceptional experience throughout their careers,” said Beth Mueller, senior vice president, People Resources. “While we have continued to grow this year, our commitment to transforming the lives of patients and our employees has not changed. We want to create an environment where people can do their best work, and we are honored to be recognized for our efforts.”
BioSpace, the leading source for life sciences news and careers, includes 60 U.S. operating employers in its Best Places to Work list that have been recognized as the most sought-after in the industry by the life sciences community.
This is BioSpace’s third Best Places to Work list. The list demonstrates a company’s desirability in the recruitment marketplace, based on the votes and ratings of thousands of life science community members. BioSpace considers each organization’s merits with particular emphasis on culture, career growth and development opportunities, leadership and innovation.
About Best Places to Work
Nominations for Best Places to Work were open in June, 2023. Voting was conducted in August, 2023. BioSpace reviewed the votes and rankings submitted by more than 2,000 life sciences professionals. Respondents were asked to identify their top three most desirable biopharma companies, segmented by large (more than 1,000+ employees) and small (less than 1,000 employees) companies. Respondents were also asked to rate their top choice organization on attributes, including compensation, innovation, career growth opportunities, leadership, culture, diversity, equity and inclusion, reputation, and flexibility and remote work.
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Learn more and subscribe at www.biospace.com.
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. It is developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and a planned Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. Its preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, for the treatment of autoimmune and inflammatory diseases. In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist antibody (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) in second line NSCLC. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X.
Senior Director, Investor Relations and Strategic Communications